The neurotransmitter serotonin (5-HT) has been implicated in various physiological functions (e.g. memory, appetite, thermoregulation, sleep, nociception, sexual behavior) and in certain pathological/psychopathological conditions (e.g. depression, anxiety, Alzheimers disease, hallucinogenic behavior). With the relatively recent discovery of multiply populations of central 5-HT binding/receptor sites (e.g. 5-HT1A, 5-HT1B, 5- HT1C, 5-HT1D, 5-HT2) comes the possibility to ascribe a specific 5-HT-related effect to a particular type of 5-HT receptor. Unfortunately, rather little is known concerning the pharmacological and functional relevance of these receptors because of the lack of site-selective agonists and antagonists. The primary purpose of this proposal is (a) to develop high- affinity, site-selective 5-HT agonists and antagonists, (b) to evaluate these agents in pharmacological procedures that have proven useful, and (c) to develop an understanding of the molecular assemblies responsible for serotonergic affinity and selectivity. Specifically, we initially propose to synthesize certain aminotetralin analogs (5-HT1A antagonists), aryloxyalkylamines (5-HT1A antagonists), 4-alkylphenalkylamines (5-HT1C agonists and antagonists), aryloxyaminoalkyl amides (5-HT1A agonists and antagonists), and 4-alkyl 2,5-dimethoxyphenalkylamines (5-HT2 antagonists). Radioligand binding will be utilized to determine the affinity and selectivity of these agents for 5-HT (and other neurotransmitter) sites and the drug discrimination paradigm with rats as subjects, as well as other pharmacological studies, will be employed to document agonist vs antagonist activity. Over the last several years, an extensive series of preliminary studies was conducted in our laboratories; we now wish to exploit leads that we have developed. The long range goals of our work include the development of site- selective agents that will be useful for the evaluation of the functional significance of 5-HT receptors. Once agents with optimal affinity/selectivity have been obtained, they may be labeled for use in radioligand binding and autoradiographic studies. Such agents can also be utilized as new training drugs in future drug discrimination studies. Certain sites have not been thoroughly characterized (e.g. 5-HT1D, 5-HT3) or have not yet been identified in human brain (5-HT1B, 5-HT3); studies similar to those described above can ultimately be used to identify/study agents selective for these sites.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS023520-03
Application #
3407116
Study Section
Neurological Sciences Subcommittee 1 (NLS)
Project Start
1988-07-01
Project End
1991-06-30
Budget Start
1990-07-01
Budget End
1991-06-30
Support Year
3
Fiscal Year
1990
Total Cost
Indirect Cost
Name
Virginia Commonwealth University
Department
Type
Schools of Pharmacy
DUNS #
City
Richmond
State
VA
Country
United States
Zip Code
23298
Young, R; Glennon, R A (1992) Zacopride and its optical isomers produce stereoselective antagonism of a 2-methylserotonin discriminative stimulus. Eur J Pharmacol 212:117-9
Glennon, R A; Young, R; Dukat, M (1992) 5-HT3 agonist 2-methylserotonin as a training drug in discrimination studies. Pharmacol Biochem Behav 41:361-4
Glennon, R A (1991) Serotonin receptors and site-selective agents. J Physiol Pharmacol 42:49-60
Raghupathi, R K; Rydelek-Fitzgerald, L; Teitler, M et al. (1991) Analogues of the 5-HT1A serotonin antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine with reduced alpha 1-adrenergic affinity. J Med Chem 34:2633-8
Glennon, R A; Dukat, M (1991) Serotonin receptors and their ligands: a lack of selective agents. Pharmacol Biochem Behav 40:1009-17
Seggel, M R; Yousif, M Y; Lyon, R A et al. (1990) A structure-affinity study of the binding of 4-substituted analogues of 1-(2,5-dimethoxyphenyl)-2-aminopropane at 5-HT2 serotonin receptors. J Med Chem 33:1032-6
Glennon, R A (1990) Do classical hallucinogens act as 5-HT2 agonists or antagonists? Neuropsychopharmacology 3:509-17
Glennon, R A; Ismaiel, A E; McCarthy, B G et al. (1989) Binding of arylpiperazines to 5-HT3 serotonin receptors: results of a structure-affinity study. Eur J Pharmacol 168:387-92
Glennon, R A; Naiman, N A; Pierson, M E et al. (1989) N-(phthalimidoalkyl) derivatives of serotonergic agents: a common interaction at 5-HT1A serotonin binding sites? J Med Chem 32:1921-6
Glennon, R A; Naiman, N A; Lyon, R A et al. (1988) Arylpiperazine derivatives as high-affinity 5-HT1A serotonin ligands. J Med Chem 31:1968-71